These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 19415181)
1. Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Buckner JC; Forouzesh B; Erlichman C; Hidalgo M; Boni JP; Dukart G; Berkenblit A; Rowinsky EK Invest New Drugs; 2010 Jun; 28(3):334-42. PubMed ID: 19415181 [TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Hidalgo M; Buckner JC; Erlichman C; Pollack MS; Boni JP; Dukart G; Marshall B; Speicher L; Moore L; Rowinsky EK Clin Cancer Res; 2006 Oct; 12(19):5755-63. PubMed ID: 17020981 [TBL] [Abstract][Full Text] [Related]
3. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. Spunt SL; Grupp SA; Vik TA; Santana VM; Greenblatt DJ; Clancy J; Berkenblit A; Krygowski M; Ananthakrishnan R; Boni JP; Gilbertson RJ J Clin Oncol; 2011 Jul; 29(21):2933-40. PubMed ID: 21690471 [TBL] [Abstract][Full Text] [Related]
4. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Diaz-Padilla I; Hirte H; Oza AM; Clarke BA; Cohen B; Reedjik M; Zhang T; Kamel-Reid S; Ivy SP; Hotte SJ; Razak AA; Chen EX; Brana I; Wizemann M; Wang L; Siu LL; Bedard PL Invest New Drugs; 2013 Oct; 31(5):1182-91. PubMed ID: 23860641 [TBL] [Abstract][Full Text] [Related]
5. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors. Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774 [TBL] [Abstract][Full Text] [Related]
6. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Khawaja MR; Nick AM; Madhusudanannair V; Fu S; Hong D; McQuinn LM; Ng CS; Piha-Paul SA; Janku F; Subbiah V; Tsimberidou A; Karp D; Meric-Bernstam F; Lu KH; Naing A Cancer Chemother Pharmacol; 2016 May; 77(5):973-7. PubMed ID: 27014780 [TBL] [Abstract][Full Text] [Related]
7. Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma. Fishman MN; Srinivas S; Hauke RJ; Amato RJ; Esteves B; Cotreau MM; Strahs AL; Slichenmyer WJ; Bhargava P; Kabbinavar FF Eur J Cancer; 2013 Sep; 49(13):2841-50. PubMed ID: 23726267 [TBL] [Abstract][Full Text] [Related]
8. Temsirolimus. Stock C; Zaccagnini M; Schulze M; Teber D; Rassweiler JJ Recent Results Cancer Res; 2010; 184():189-97. PubMed ID: 20072839 [TBL] [Abstract][Full Text] [Related]
9. A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies. Trivedi ND; Armstrong S; Wang H; Hartley M; Deeken J; Ruth He A; Subramaniam D; Melville H; Albanese C; Marshall JL; Hwang J; Pishvaian MJ Cancer Med; 2021 Mar; 10(6):1944-1954. PubMed ID: 33638305 [TBL] [Abstract][Full Text] [Related]
10. Temsirolimus in patients with advanced renal cell carcinoma: an overview. Bhatia S; Thompson JA Adv Ther; 2009 Jan; 26(1):55-67. PubMed ID: 19172239 [TBL] [Abstract][Full Text] [Related]
11. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410 [TBL] [Abstract][Full Text] [Related]
12. Eosinophilic rash secondary to temsirolimus. Gandhi M; Kuzel T; Lacouture M Clin Genitourin Cancer; 2009 Aug; 7(2):E34-6. PubMed ID: 19692320 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma. Sun Y; Rha S; Lee SH; Guo J; Ueda T; Qin S; Naito S; Cincotta M; Tokushige K; Akaza H Jpn J Clin Oncol; 2012 Sep; 42(9):836-44. PubMed ID: 22844126 [TBL] [Abstract][Full Text] [Related]
15. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. Tabernero J; Rojo F; Calvo E; Burris H; Judson I; Hazell K; Martinelli E; Ramon y Cajal S; Jones S; Vidal L; Shand N; Macarulla T; Ramos FJ; Dimitrijevic S; Zoellner U; Tang P; Stumm M; Lane HA; Lebwohl D; Baselga J J Clin Oncol; 2008 Apr; 26(10):1603-10. PubMed ID: 18332469 [TBL] [Abstract][Full Text] [Related]
16. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. Boni JP; Hug B; Leister C; Sonnichsen D Semin Oncol; 2009 Dec; 36 Suppl 3():S18-25. PubMed ID: 19963096 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. Chan S; Scheulen ME; Johnston S; Mross K; Cardoso F; Dittrich C; Eiermann W; Hess D; Morant R; Semiglazov V; Borner M; Salzberg M; Ostapenko V; Illiger HJ; Behringer D; Bardy-Bouxin N; Boni J; Kong S; Cincotta M; Moore L J Clin Oncol; 2005 Aug; 23(23):5314-22. PubMed ID: 15955899 [TBL] [Abstract][Full Text] [Related]
18. A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. Infante JR; Cohen RB; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; LoRusso PM Invest New Drugs; 2017 Oct; 35(5):576-588. PubMed ID: 28424891 [TBL] [Abstract][Full Text] [Related]
19. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Kwitkowski VE; Prowell TM; Ibrahim A; Farrell AT; Justice R; Mitchell SS; Sridhara R; Pazdur R Oncologist; 2010; 15(4):428-35. PubMed ID: 20332142 [TBL] [Abstract][Full Text] [Related]
20. A phase I study of temsirolimus and metformin in advanced solid tumours. MacKenzie MJ; Ernst S; Johnson C; Winquist E Invest New Drugs; 2012 Apr; 30(2):647-52. PubMed ID: 20978924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]